SOURCE: Medistem Inc.

Medistem Inc.

April 19, 2010 23:38 ET

Intravenous Administration of Endometrial Regenerative Cells (ERC) Induces Benefit in Heart Failure Patient

Third Peer-Reviewed Medical Paper Describing Clinical Use of ERC

SAN DIEGO, CA--(Marketwire - April 19, 2010) -  Medistem Inc. (PINKSHEETS: MEDS) reported today a recent publication in the peer reviewed journal International Archives of Medicine describing a 74 year old heart failure patient treated with the company's endometrial regenerative cell (ERC) product in November 2007. The patient's ejection fraction, meaning the heart's pumping activity, increased from 25-30% pre-treatment to 40% in June of 2008. The increase was maintained when the patient was re-examined in August 2008 and October 2009. Substantial quality of life improvement was noted as assessed by the Minnesota Quality of Life Questionnaire Score which dropped from 97 pre-treatment to 2 in February 2009. No treatment associated adverse events were noted in the follow-up.

"We have previously published that the ERC stem cells can differentiate into heart, liver, lung, brain, bone, fat, muscle, blood vessel, and cartilage tissue (Meng et al. J Transl Med. 2007 Nov 15;5:57). While heart failure is not our primary indication, we are enthusiastic that our collaborators have published this data, which may be the stepping stone for future investigations," said Thomas Ichim, CEO of Medistem.

The current publication is the third description in the peer-reviewed literature of ERC being clinically used. The first paper (Zhong et al. J Transl Med. 2009 Feb 20;7:15) reported safety parameters of ERC administration intravenously and intrathecally, and the second paper (Ichim et al. Cell Immunol. 2010;260(2):75-82) described improvements in a patient with Duchenne's Muscular Dystrophy after ERC treatment.

"The advantage of ERC over existing stem cell approaches include: ease of administration, lack of need for donor-recipient matching, and ability to generate large quantities of ERC in an economical manner," said Thomas Ichim. "An SBIR grant is currently funding preclinical experiments requested by the FDA in response to our filed IND. We are excited about the prospects of clinical trials in the United States."

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Thomas E Ichim
    Chief Executive Officer
    Medistem Inc.
    9255 Towne Centre Drive
    Suite 450
    San Diego CA 92122
    858 349 3617
    858 642 0027